GET DAILY SIGNALSCo-Diagnostics (CODX) Drops 76% in 30 Days on Liquidity Pressures
Key Takeaways
- Co-Diagnostics shares declined roughly 76% over the last 30 days, falling from about $1.07 to around $0.25 as liquidity concerns outweighed a headline earnings beat.
- Third-quarter 2026 results topped consensus estimates, yet the stock continued to slide amid a thin cash balance and new financing arrangements.
- The company reported about $714,803 in cash and cash equivalents as of September 30, 2026, and completed a senior secured convertible debt financing after the quarter, heightening dilution concerns.
- A registration statement to offer up to 39.59 million shares for selling stockholders added further supply overhang to the stock.
- The Co-Dx PCR platform remains under regulatory review and is not yet cleared for sale; two submissions are pending in the United States and India.
- Over the last quarter, the stock has fallen roughly 83%, extending a sustained multi-month downtrend.
- For additional context on valuation and catalysts, review the Price Targets, Earnings, and Forecast pages for CODX.
Company Background and Market Position
Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, that develops, manufactures, and markets diagnostic technologies built around the detection and analysis of nucleic acids (DNA and RNA). The company is best known for its proprietary Co-Dx PCR platform, which includes the PCR Home and PCR Pro instruments and a mobile app designed for point-of-care and at-home testing. That platform is subject to regulatory review and is not yet cleared for commercial sale.
The company also operates through joint ventures, most notably CoSara Diagnostics in India, which is advancing a point-of-care tuberculosis (TB) test toward regulatory clearance and a potential commercial launch. Investors follow CODX for its pipeline of infectious-disease tests, its push into decentralized molecular testing, and its exposure to high-burden diagnostic markets such as India, where tuberculosis remains a major public-health challenge. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Past 30 Days and Quarter
Over the last 30 days, CODX fell from a closing price of about $1.07 on October 13, 2026, to roughly $0.25 in the most recent session, a decline of approximately 76%. The move was steep and largely one-directional, with a sharp selloff in mid-October followed by additional leg lower into November.
The quarterly picture is even more pronounced. Approximately three months earlier, the stock traded near $1.48, meaning the share price has dropped roughly 83% over the last quarter. This reflects a persistent downtrend rather than a single-session shock, as repeated financing-related and liquidity-driven selloffs compounded on one another. From what I see, the trend lines on Tickeron’s AI Trend Prediction Engine align with this extended weakness.
Factors Behind the Recent 30-Day Decline
The recent decline was driven primarily by balance-sheet and dilution concerns rather than operating performance. In its third-quarter 2026 results reported on November 10, Co-Diagnostics posted revenue of $282,881, up from $145,380 a year earlier, and a net loss of $6.3 million, or $1.01 per share. Both the loss per share and revenue came in ahead of consensus estimates, but the stock still weakened.
The more consequential disclosures centered on liquidity. The company ended the quarter with approximately $714,803 in cash and cash equivalents, a level that raised questions about its runway to fund continued development. After the quarter ended, Co-Diagnostics completed a senior secured convertible debt financing with roughly $2.1 million in initial funding, an arrangement that introduced additional dilution risk. Separately, a registration statement filed with the SEC covering up to 39.59 million shares for selling stockholders added supply overhang, while a proxy filing seeking broad authority for a potential reverse stock split underscored the pressure on the share price.
Drivers of Performance Over the Last Quarter
The broader quarterly decline reflects a company in transition that is still funding a pre-revenue product pipeline. Although Co-Diagnostics has advanced key regulatory milestones, the Co-Dx PCR platform has not yet received marketing authorization, meaning the company's primary growth opportunity remains ahead of it while operating losses and cash burn continue in the interim.
During the quarter, the company submitted its Flu A/B & RSV test to the U.S. Food and Drug Administration through a 510(k) notification and concurrent CLIA Waiver by Application, and its joint venture CoSara submitted a point-of-care tuberculosis test to India's Central Drugs Standard Control Organisation. It also announced a collaboration with ReadyGo Diagnostics to evaluate blood-based molecular testing. These developments provided pipeline momentum, but the market's focus remained on the company's cash position and the dilutive financing required to bridge to potential commercialization.
Key Areas to Watch Going Forward
Investors monitoring CODX should focus on several forward-looking factors. The first is regulatory progress: the outcomes of the FDA review of the Flu A/B & RSV test and the CDSCO review of the tuberculosis test in India will be central to the company's commercial story. The company has indicated it anticipates a potential India launch for the TB test before year-end, and any clearance or delay would likely influence sentiment.
Second, liquidity and financing remain critical. The company's ability to secure additional capital on manageable terms, the pace of cash burn, and any further dilutive activity or reverse-split actions will be closely watched. Finally, the progression of the ReadyGo blood-based testing collaboration and the company's first international Vector Smart deployment could shape the longer-term narrative. These factors should be weighed alongside the inherent risks of a development-stage diagnostics business, and they are not a basis for investment decisions. I’m watching this closely with the help of Tickeron’s AI Pattern Search Engine for any emerging signals.
Using AI Trading Bots in My Research
In my own analysis process, I often review Tickeron’s AI Trading Bots to see how automated strategies are handling names like CODX under current market conditions. These bots cover a range of approaches from short-term momentum to longer-term trend following, and checking their recent signals gives me an additional data point when evaluating high-volatility development-stage stocks. It takes just a few minutes to compare performance metrics and helps keep my thinking grounded in systematic observations rather than isolated headlines.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CODX in downward trend: price dove below 50-day moving average on October 13, 2026
CODX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend. In 37 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CODX as a result. In 74 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CODX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CODX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CODX just turned positive on November 11, 2026. Looking at past instances where CODX's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
CODX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.142). P/E Ratio (-0.010) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.171) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. CODX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CODX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of molecular diagnostics products and tests that represents a radical new advancement in the understanding of the molecular interactions of DNA
Industry MedicalNursingServices
Advertisement